Katja Rudell, PhD, MSc, CPsychol

Katja is the Service Line lead for clinical outcomes assessments. She helps Parexel’s clients develop and validate new COA instruments and surveys for use across the drug development life span (I-IV). Katja is the Founding Chair of the Special Interest Group for COA at ISPOR.

Work experience

Katja worked previously in 2 COA Centres of Excellence at Pfizer 2008-2015, AZ 2016-17 and oversaw the implementation of pharma sponsored patient services for the UK and Irish region for Shire’s rare disease portfolio 2017-2019. She has been working in respiratory, neuroscience, oncology and rare disease drug development and joined Parexel in 2019 to develop COA services.

Education

Katja obtained 2 postgraduate degrees (MSc, PhD) from the University of London. She worked at the University of Kent 2004-2008 as a lecturer prior to joining Pfizer Outcomes Research Department in Sandwich, UK.